相似文献
1
Chronic inflammatory demyelinating polyradiculoneuropathy complicating anti TNF α therapy for chronic plaque psoriasis.
BMJ Case Rep. 2011 Dec 1;2011:bcr0820114674. doi: 10.1136/bcr.08.2011.4674.
2
Bilateral facial nerve palsies secondary to chronic inflammatory demyelinating polyneuropathy following adalimumab treatment.
Clin Neurol Neurosurg. 2018 Jan;164:64-66. doi: 10.1016/j.clineuro.2017.11.001. Epub 2017 Nov 22.
3
Development of sarcoidosis during adalimumab therapy for chronic plaque psoriasis.
Australas J Dermatol. 2011 Aug;52(3):e8-11. doi: 10.1111/j.1440-0960.2010.00660.x. Epub 2010 Jun 23.
4
Chronic inflammatory demyelinating polyneuropathy and psoriasis comorbidity with significantly alleviated in symptoms after secukinumab: case report.
BMC Neurol. 2022 Nov 2;22(1):400. doi: 10.1186/s12883-022-02928-3.
5
The development of chronic inflammatory demyelinating polyneuropathy during adalimumab treatment in a patient with psoriasis vulgaris.
Eur J Dermatol. 2016 Aug 1;26(4):404-5. doi: 10.1684/ejd.2016.2781.
6
DADS neuropathy associated with anti-TNF-α therapy.
BMJ Case Rep. 2015 Nov 25;2015:bcr2015211781. doi: 10.1136/bcr-2015-211781.
7
Steroid-induced inflammatory neuropathy in a patient on tumor necrosis factor-α antagonist therapy.
J Clin Neuromuscul Dis. 2010 Dec;12(2):88-90. doi: 10.1097/CND.0b013e3181fd9401.
8
Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor-alpha antagonists.
Muscle Nerve. 2010 May;41(5):723-7. doi: 10.1002/mus.21584.
9
Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients.
Br J Dermatol. 2011 Mar;164(3):645-7. doi: 10.1111/j.1365-2133.2010.10140.x. Epub 2011 Feb 7.
10
Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE.
J Eur Acad Dermatol Venereol. 2011 Sep;25(9):1012-20. doi: 10.1111/j.1468-3083.2010.03944.x. Epub 2011 Jan 9.
引用本文的文献
1
Neurological Side Effects of TNF-α Inhibitors Revisited: A Review of Case Reports.
Medicina (Kaunas). 2024 Aug 28;60(9):1409. doi: 10.3390/medicina60091409.
2
Chronic inflammatory demyelinating polyneuropathy and psoriasis comorbidity with significantly alleviated in symptoms after secukinumab: case report.
BMC Neurol. 2022 Nov 2;22(1):400. doi: 10.1186/s12883-022-02928-3.
3
Neurological Complications of Therapeutic Monoclonal Antibodies: Trends from Oncology to Rheumatology.
Curr Neurol Neurosci Rep. 2017 Aug 17;17(10):75. doi: 10.1007/s11910-017-0785-3.
4
Guillain-Barré syndrome in association with antitumour necrosis factor therapy: a case of mistaken identity.
BMJ Case Rep. 2017 Jul 5;2017:bcr-2017-219481. doi: 10.1136/bcr-2017-219481.
5
Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.
Cochrane Database Syst Rev. 2017 May 8;5(5):CD003280. doi: 10.1002/14651858.CD003280.pub5.
6
Transcriptome Analysis of Peripheral Blood in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients Identifies TNFR1 and TLR Pathways in the IVIg Response.
Medicine (Baltimore). 2016 May;95(19):e3370. doi: 10.1097/MD.0000000000003370.
7
Non-length-dependent and length-dependent small-fiber neuropathies associated with tumor necrosis factor (TNF)-inhibitor therapy in patients with rheumatoid arthritis: expanding the spectrum of neurological disease associated with TNF-inhibitors.
Semin Arthritis Rheum. 2014 Apr;43(5):638-47. doi: 10.1016/j.semarthrit.2013.10.007. Epub 2013 Oct 30.
本文引用的文献
1
Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor-alpha antagonists.
Muscle Nerve. 2010 May;41(5):723-7. doi: 10.1002/mus.21584.
2
Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy.
Arch Neurol. 2009 Apr;66(4):490-7. doi: 10.1001/archneurol.2009.11.
3
Demyelination and inhibition of tumor necrosis factor (TNF).
Clin Exp Rheumatol. 2004 Sep-Oct;22(5 Suppl 35):S134-40.
4
Recurrent Guillain Barre' syndrome.
Electromyogr Clin Neurophysiol. 2004 Mar;44(2):95-102.
5
Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?
Arthritis Rheum. 2001 Sep;44(9):1977-83. doi: 10.1002/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6.
Zotero 插件